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In a recent issue of Cell, Theodoris et al. (2015) used a complex systems biology approach to model vascular
aortic calcification caused by mutations in the NOTCH1 gene. Comparison of endothelial cells from patient
hiPSCs and genetically matched controls under fluid flow revealed novel mechanisms underlying the
disease.Until recently, it was widely thought that
human diseases were caused by alter-
ations in DNA. However, largely as a result
of cancer research, epigenetic changes,
such as DNA methylation and histone
modifications, are also widely appreci-
ated as major contributing factors. Car-
diovascular diseases are among the
conditions now considered to have an
epigenetic component, as recent ‘‘epi-
demics’’ associated with aging, stress,
and lifestyle cannot be explained by
genomic changes only. Recent studies
on atherosclerosis or type 2 diabetes, for
example, indicate that underlying cardio-
vascular risk can develop in utero through
epigenetic mechanisms (DeRuiter et al.,
2008; Johnstone and Baylin, 2010).
Nevertheless, studying mechanisms un-
derlying transcriptional and epigenetic
changes associated with cardiovascular
disease remains difficult despite its high
incidence because affected cardiomyo-
cytes and endothelial cells (ECs) can
rarely be obtained in the large numbers
required for laboratory experiments. At
most, small biopsies are available from
patients.
Srivastava’s group now elegantly dem-
onstrates the value of human induced
pluripotent stem cells (hiPSCs) in ad-
dressing this challenge. They generated
a genetic model of calcified aortic valve
disease (CAVD) based on ECs from pa-
tient hiPSCs with NOTCH1 mutations
(Figure 1) (Theodoris et al., 2015). Aortic
valve calcification is a leading cause of
heart disease. A major risk factor is
‘‘bicuspid aortic valve,’’ where two ‘‘leaf-
lets’’ form during development rather
than the usual three. Leaflets are made
of fibrous tissue lined with ECs; they
ensure that blood flows from the leftventricle of the heart to the aorta. Cur-
rently, the only treatment for CAVD is
valve replacement because calcification
cannot be reversed, partly because the
underlying mechanisms are poorly under-
stood. Disturbed blood flow through the
aortic valve is the major cause of later
calcification (Weinberg et al., 2010). The
leaflets on the ventricular side of the valve
experience a spike of shear force when
blood enters the artery from the left
ventricle. The aortic side of the valve, by
contrast, undergoes much less shear
and is more prone to calcification. Srivas-
tava’s group showed previously that
mutations in the NOTCH1 gene are asso-
ciated with familial and sporadic bicuspid
and calcified aortic valves (Garg et al.,
2005). Since NOTCH signaling is higher
on the ventricular side, it is considered
protective for calcification (Wirrig and Yut-
zey, 2011).
NOTCH is part of a highly conserved
signaling pathway that regulates many
different cellular functions, from self-
renewal to differentiation, and NOTCH-
regulated transcriptional responses differ
remarkably in each cell type (Andersson
et al., 2011). NOTCH signaling is highly
sensitive to the gene dose, so haploinsuf-
ficiency for NOTCH receptors or ligands
caused bymutations often results in aber-
rant cell behavior, and this is the case for
CAVD. In addition, deletion of the NOTCH
ligand Jagged1 also results in aortic valve
calcification, confirming the critical role of
this pathway in CAVD (Hofmann et al.,
2012).
Theodoris et al. therefore focused on
characterization of NOTCH1-dependent
transcriptional and epigenetic mecha-
nisms in ECs. This cellular context has
not been examined before and is likelyCell Stem Cederegulated in the disease state. Isogenic
controls were created when Theodoris
et al. ‘‘repaired’’ the NOTCH1 mutations
in patient hiPSCs by transcription acti-
vator-like effector nucleases (TALENs).
The authors then used an efficient EC
differentiation protocol previously devel-
oped in their group to generate large
numbers of ECs from hiPSCs (White
et al., 2013). First, transcriptional and
epigenetic changes during EC differentia-
tion were examined. Since NOTCH1 reg-
ulates many steps in early development,
this experiment allowed identification of
the set of genes affected by NOTCH1
haploinsufficiency to be narrowed down
to those specifically expressed in ECs.
Next, fluid flow-mediated responses
were investigated in hiPSC-derived ECs.
For this, the authors cultured ECs in
either a microfluidic or custom-built par-
allel flow chamber to study the effect of
laminar shear stress that is normally
observed in arteries (12,5 dyn/cm2) on
gene expression or histone modifications
by chromatin immunoprecipitation seq-
uencing (CHIP-seq). Interestingly, shear
stress resulted in activation of anti-osteo-
genic molecules and repression of pro-
inflammatory signatures in hiPSC-derived
ECs that correlated with the occupancy
of their enhancers by repressive or active
chromatin marks. By contrast, the inflam-
matory proteins STAT6, NFKB2, and IRF9
were enriched under static conditions, in
addition to key predictive shear stress
genes like SMAD6. SMAD6 inhibits BMP
signaling, which induces calcification.
Loss of Smad6 in mice results in aortic
calcification (Galvin et al., 2000). Interest-
ingly, these transcriptional changes also
correlated with changes in the epigenetic
state of the cells. Analysis of histonell 16, May 7, 2015 ª2015 Elsevier Inc. 455
Figure 1. Model of Calcified Aortic Valve Disease ‘‘In a Dish’’
Endothelial cells (ECs) were derived from patient hiPSCs with a NOTCH1mutation (hiPSCs-NOTCH1mutant) and isogenic ‘‘corrected’’ controls (hiPSC-NOTCH1
wt). Gene expression, histone modifications, and DNA methylation was compared under ‘‘static’’ and fluid ‘‘flow’’ culture conditions. This revealed a molecular
mechanism that explained valve calcification in hiPSC-NOTCH1 mutant ECs specifically on the ventricular side of the valve where NOTCH1 activity is decreased
by differential blood flow. The illustration is courtesy of Bas Blankevoort.
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ment of pro-inflammatory genes (STAT
and IRF) in active enhancers marked
by H3K27ac. Moreover, shear stress
caused preferential activation of anti-
inflammatory enhancers, anti-oxidants,
and TGF-b inhibitory signaling. Further-
more, Smad2/3/4 motifs co-existed with
repressive H3K27me3 signature. There
was thus a clear relationship between
shear stress, inflammation, and genetic/
epigenetic status in hiPSC-derived ECs.
The NOTCH1-deficient hiPSC ECs
were next compared to controls under
similar static and laminar flow condi-
tions. NOTCH1-deficient ECs exhibited
increased pro-inflammatory gene expres-
sion and failed to activate an anti-osteo-
genic program upon shear stress. This
aberrant transcriptional response corre-
lated with the distribution of active and
repressive chromatin marks. Active chro-
matin marked by H3K27ac was increased
in pro-inflammatory STAT and IRF
motifs under static and shear conditions456 Cell Stem Cell 16, May 7, 2015 ª2015 Elin NOTCH1-deficient ECs. Examination
of repressive chromatin marks with
H3K27me3 showed re-activation of pro-
osteogenic BMP signaling. The inflam-
matory and ‘‘calcification’’ response of
NOTCH1 mutant ECs was thus different
from that of their controls under shear
stress and this could be explained by dif-
ferences in their epigenetic status.
Finally, the authors identified a gene
regulatory network in NOTCH1-deficient
ECs indicating novel targets, such as
ARHGEF7, as well as key regulatory
‘‘node genes.’’ Among the dysregulated
genes, SOX7, TCF4, and SMAD1 were
the most interconnected. The authors
next attempted rescue of the phenotype
in NOTCH1-deficient ECs with siRNA
against the node genes. Modifying SOX7
and TCF4 expression with siRNA re-
sulted in downregulated pro-inflamma-
tory genes and upregulated anti-osteo-
genic factors, identifying a potential new
route to treat calcification in patients at
risk.sevier Inc.The work by Theodoris et al. sets a
new standard for genetic disease
modeling and drug screening using
hiPSCs. Their comprehensive analysis
involved characterization of all key EC
differentiation steps at the transcrip-
tional and epigenetic level. This in
itself adds invaluable bioinformatics
data to that already published on lineage
commitment of hiPSCs. In addition, this
study demonstrates that patient-specific
hiPSC-derived ECs recapitulate a dis-
ease phenotype and thus that similar
approaches could be used to study
mechanisms of different vascular genetic
disease. More specifically, diseased ECs
exhibited aberrant genetic and epige-
netic responses that were different under
static or shear stress conditions. As in
primary ECs, shear stress responses in
control hiPSC-derived ECs induced tran-
scriptional and epigenetic regulation of
anti-osteogenic, anti-inflammatory, and
anti-oxidant pathways, which were abro-
gated by NOTCH1 haploinsufficiency.
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exceptionally comprehensive analysis
facilitated extraction of information
about interconnectivity of dysregulated
genes and identification of novel key
regulatory node genes that might be
important for aortic calcification. Thus,
the work by Theodoris et al. represents
a significant step forward in shedding
light on the mechanism of aortic valve
calcification, the epigenome and tran-
scriptome in a human disease model
of which can be altered by dose-reduc-
tion of a transcription factor, illustrating
possible pathways for therapeutic
intervention.REFERENCES
Andersson, E.R., Sandberg, R., and Lendahl, U.
(2011). Development 138, 3593–3612.
DeRuiter, M.C., Alkemade, F.E., Gittenberger-de
Groot, A.C., Poelmann, R.E., Havekes, L.M., and
van Dijk, K.W. (2008). Curr. Opin. Lipidol. 19,
333–337.
Galvin, K.M., Donovan, M.J., Lynch, C.A., Meyer,
R.I., Paul, R.J., Lorenz, J.N., Fairchild-Huntress,
V., Dixon, K.L., Dunmore, J.H., Gimbrone, M.A.,
et al. (2000). Nat. Genet. 24, 171–174.
Garg, V., Muth, A.N., Ransom, J.F., Schluterman,
M.K., Barnes, R., King, I.N., Grossfeld, P.D., and
Srivastava, D. (2005). Nature 437, 270–274.
Hofmann, J.J., Briot, A., Enciso, J., Zovein, A.C.,
Ren, S., Zhang, Z.W., Radtke, F., Simons, M.,Cell Stem CeWang, Y., and Iruela-Arispe, M.L. (2012). Develop-
ment 139, 4449–4460.
Johnstone, S.E., and Baylin, S.B. (2010). Nat. Rev.
Genet. 11, 806–812.
Theodoris, C.V., Li, M., White, M.P., Liu, L., He, D.,
Pollard, K.S., Bruneau, B.G., and Srivastava, D.
(2015). Cell 160, 1072–1086.
Weinberg, E.J., Mack, P.J., Schoen, F.J., Garcı´a-
Carden˜a, G., and Kaazempur Mofrad, M.R.
(2010). Cardiovasc. Eng. 10, 5–11.
White, M.P., Rufaihah, A.J., Liu, L., Ghebremariam,
Y.T., Ivey, K.N., Cooke, J.P., and Srivastava, D.
(2013). Stem Cells 31, 92–103.
Wirrig, E.E., and Yutzey, K.E. (2011). Cardiovasc.
Pathol. 20, 162–167.Converting a Problem into an Opportunity:
mtDNA Heteroplasmy ShiftAntonio Diez-Juan1 and Carlos Simo´n1,2,3,*
1Igenomix, Parc Cientific Valencia University, 46980 Paterna, Valencia, Spain
2Fundacio´n Instituto Valenciano de Infertilidad (FIVI), Department of Obstetrics & Gynecology, School of Medicine, Valencia University and
Instituto Universitario IVI/INCLIVA, 46015 Valencia, Spain
3Department of Obstetrics and Gynecology, Stanford University, Palo Alto, CA 94304, USA
*Correspondence: carlos.simon@uv.es
http://dx.doi.org/10.1016/j.stem.2015.04.012
The transmission of mitochondrial DNA (mtDNA) disease from a mother with a heteroplasmic mtDNA muta-
tion to her children is unpredictable. In a recent issue of Cell, Reddy et al. (2015) present the potential for
mitochondrial-targeted nucleases to remove mutated mtDNA through the induction of heteroplasmy shift
in oocytes and zygotes.Mitochondria are the centerpiece of
cellular metabolic machinery and contain
multiple copies of a small genome, the
mtDNA. Because an individual cell con-
tains hundreds of mitochondria, each
with its own varying genome, there is a
substantial amount of mitochondrial
genomic diversity, and this phenomenon
is referred to as mtDNA heteroplasmy.
Diseases associated with mtDNA muta-
tions are unexpectedly common and
represent a broad range of deteriorating
conditions. The estimated incidence of
mtDNA disease in adults is 1 in 5,000,
but low levels of pathogenic mutations
have been detected in 1 out of 200
births. Pathogenic mutations provoke
symptoms only when mutant mtDNA isabove a specific threshold, and every
new mtDNA mutation creates a hetero-
plasmic mixture. Thus, a shift, or change
in percentage of mutant alleles through
replicative segregation, in mtDNA hetero-
plasmy is responsible for the pathoge-
nicity of mitochondrial diseases. The
mechanism by which this segregation
occurs in either somatic or germ cells re-
mains unknown (Wai et al., 2008). Impor-
tantly, mutated copies of mtDNA in the
oocyte are transmitted to the embryo,
but transmission of mtDNA disease from
a mother with a heteroplasmic mtDNA
mutation to her children is unpredictable.
Preimplantation genetic diagnosis of em-
bryos in affected mothers can reduce,
but not eliminate, mitochondrial diseasedue to uncontrolled heteroplasmy. There-
fore, affected mothers have no real
choices for having healthy children except
to play a form of reproductive ‘‘roulette,’’
where they are left to choose between
risking the possibility of their child having
disabilities and a shortened life or termi-
nating their pregnancy.
In a recent issue ofCell, Reddy and col-
leagues address this issue by exploiting
mtDNA heteroplasmy as a therapeutic
opportunity rather than an insurmount-
able problem (Reddy et al., 2015). Also,
they take advantage of the poor capacity
of the mitochondria to repair damaged
mtDNA. To this end they use mitochon-
drial-targeted nucleases to remove
mutated mtDNA in oocytes and zygotesll 16, May 7, 2015 ª2015 Elsevier Inc. 457
